Plotting the longevity market on two axes reveals the mismatch between where capital flows and where integration is needed:

Top Left (high capital, low integration): Cellular reprogramming, gene/RNA therapeutics—speculative, high-risk, minimal primary-care fit today

Top Right (high capital, moderate-high integration potential): Senolytics, autophagy modulators—mechanistically sound, closer to primary-care indications

Middle Right (moderate capital, high integration potential): Preventive data platforms, well-validated biomarkers, metabolic programs integrated with chronic-disease care

Bottom Left (low capital, low integration): Cryonics, HBOT-for-longevity, speculative stacks

Bottom Right (low-moderate capital, high integration): Community metabolic and mental-health programs using aging-biology insights but not branded as 'longevity'

Key insight: Most capital is top-left (speculative, unintegrated). Most people are bottom-right (integrated into existing systems). This is the integration gap.

Deck 4: Ecosystem Maps & Failure Patterns

Upward: Biology → measurement → services (therapeutics generate demand for biomarkers and clinics)
Downward: Services → measurement → biology (clinic data informs platform development and new therapeutic targets)
Vertical spine: Primary care and community mental health run through all three layers as the 'current care backbone'